Why is­n't Ver­tex de­clar­ing suc­cess for its non-opi­oid pain drug in a late-stage tri­al?

Nor­mal­ly when a com­pa­ny scores on a pri­ma­ry end­point in a Phase III tri­al, those re­sults are re­leased as soon as pos­si­ble to not on­ly in­form the world, but to cel­e­brate the suc­cess.

Ver­tex’s Phase III tri­al of its drug VX-548 for acute pain af­ter a tum­my tuck or ab­domino­plas­ty com­plet­ed ear­li­er this year. But the com­pa­ny has said noth­ing about whether it hit the pri­ma­ry end­point. Though Ver­tex has said it will wait for the re­sults from two oth­er tri­als — a Phase III af­ter a bunionec­to­my, and a sin­gle-arm tri­al with dif­fer­ent pain con­di­tions — the de­lay is lead­ing to spec­u­la­tion that the first tri­al is a win.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER